Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.

Autor: Vieira Neto, Leonardo, Wildemberg, Luiz Eduardo, Moraes, Aline B., Colli, Leandro M., Kasuki, Leandro, Marques, Nelma Verônica, Gasparetto, Emerson L., Castro, Margaret, Takiya, Christina Maeda, Gadelha, Mônica R.
Předmět:
Zdroj: Clinical Endocrinology; May2015, Vol. 82 Issue 5, p739-746, 8p, 1 Color Photograph, 1 Black and White Photograph, 1 Chart, 1 Graph
Abstrakt: Objectives To determine the dopamine receptor subtype 2 (DR2) mRNA levels and protein expression and to evaluate the effect of adjuvant cabergoline therapy on tumour volume ( TV) in patients with postoperative residual nonfunctioning pituitary adenoma ( NFPA). Methods The mRNA expression was quantified by real-time RT-PCR (TaqMan®), and protein expression was evaluated by immunohistochemistry. Tumours were classified according to the percentage of immunostained cells for DR2 as scores 1 (<50% of stained cells) or 2 (≥50%). Cabergoline was started at least 6 months after surgery in nine patients with residual tumours (3 mg/week). The cabergoline effect was prospectively evaluated by magnetic resonance imaging using three-dimensional volume calculation. TV reduction >25% was considered significant. Results The DR2 mRNA expression was variable but was observed in 100% of the samples ( N = 20). DR2 protein expression was also observed in all the tumours ( N = 34). Twenty-nine tumours (85%) were classified as score 2. The median DR2 mRNA expression was higher in the tumours classified as score 2 compared with score 1 ( P = 0·007). TV reduction with cabergoline therapy was observed in 67% of the patients (6/9). The median TV before and after 6 months of treatment was 1·90 cm3 (0·61-8·74) and 1·69 cm3 (0·36-4·20) [ P = 0·02], respectively. Conclusion In conclusion, DR2 is expressed in all adenomas and the majority of the patients in this study displayed tumour shrinkage on cabergoline ( CAB) therapy. Thus, CAB might be useful in adjuvant therapy in NFPA patients with residual tumours after surgery. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index